Insmed Incorporated (NASDAQ:INSM) Shares Purchased by State of New Jersey Common Pension Fund D

State of New Jersey Common Pension Fund D boosted its position in shares of Insmed Incorporated (NASDAQ:INSM - Free Report) by 7.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 64,061 shares of the biopharmaceutical company's stock after buying an additional 4,438 shares during the period. State of New Jersey Common Pension Fund D's holdings in Insmed were worth $4,423,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Geode Capital Management LLC lifted its stake in shares of Insmed by 4.7% in the third quarter. Geode Capital Management LLC now owns 3,813,384 shares of the biopharmaceutical company's stock valued at $278,432,000 after purchasing an additional 172,664 shares during the period. Principal Financial Group Inc. increased its holdings in Insmed by 12.9% in the third quarter. Principal Financial Group Inc. now owns 1,871,890 shares of the biopharmaceutical company's stock valued at $136,648,000 after buying an additional 214,130 shares in the last quarter. Vestal Point Capital LP lifted its position in shares of Insmed by 113.3% during the 3rd quarter. Vestal Point Capital LP now owns 1,600,000 shares of the biopharmaceutical company's stock valued at $116,800,000 after acquiring an additional 850,000 shares during the period. Charles Schwab Investment Management Inc. boosted its stake in shares of Insmed by 10.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,444,266 shares of the biopharmaceutical company's stock worth $105,431,000 after acquiring an additional 137,670 shares in the last quarter. Finally, Wellington Management Group LLP grew its holdings in shares of Insmed by 2.6% in the 3rd quarter. Wellington Management Group LLP now owns 962,459 shares of the biopharmaceutical company's stock worth $70,260,000 after acquiring an additional 24,025 shares during the period.

Insider Buying and Selling

In other news, CFO Sara Bonstein sold 18,322 shares of the stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $80.31, for a total value of $1,471,439.82. Following the completion of the sale, the chief financial officer now owns 118,863 shares in the company, valued at approximately $9,545,887.53. This trade represents a 13.36 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO William Lewis sold 18,750 shares of Insmed stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $81.03, for a total transaction of $1,519,312.50. Following the sale, the chief executive officer now owns 334,186 shares in the company, valued at $27,079,091.58. This represents a 5.31 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 532,207 shares of company stock valued at $41,400,465. 4.60% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on INSM. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Insmed in a report on Wednesday. Wells Fargo & Company lifted their price target on Insmed from $85.00 to $107.00 and gave the stock an "overweight" rating in a research note on Wednesday. JPMorgan Chase & Co. boosted their price objective on shares of Insmed from $83.00 to $92.00 and gave the stock an "overweight" rating in a research report on Friday, February 7th. Morgan Stanley raised their target price on shares of Insmed from $85.00 to $90.00 and gave the company an "overweight" rating in a report on Thursday, February 6th. Finally, Guggenheim upped their price target on shares of Insmed from $95.00 to $101.00 and gave the company a "buy" rating in a report on Friday, February 7th. One research analyst has rated the stock with a sell rating and fifteen have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $91.00.

Insmed Trading Down 3.3 %

INSM traded down $2.72 during trading on Friday, hitting $80.89. The company's stock had a trading volume of 1,231,736 shares, compared to its average volume of 1,902,183. The stock has a market cap of $14.47 billion, a PE ratio of -14.49 and a beta of 1.11. The firm's 50 day moving average price is $74.11 and its 200-day moving average price is $73.52. Insmed Incorporated has a twelve month low of $21.92 and a twelve month high of $84.91. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99.

Insmed (NASDAQ:INSM - Get Free Report) last issued its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) EPS for the quarter, missing the consensus estimate of ($1.17) by ($0.15). The company had revenue of $104.44 million for the quarter, compared to analysts' expectations of $102.31 million. On average, analysts expect that Insmed Incorporated will post -5.42 earnings per share for the current year.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.